Back to search results

Relugolix Combination Therapy After Endometriosis Surgery

This study is for women aged 18 and older who are having surgery for endometriosis. It aims to see if taking a medication called Relugolix combination therapy (Rel-CT) right after surgery helps improve your quality of life and reduces the chance of endometriosis returning, compared to having surgery alone. Rel-CT is an FDA-approved treatment for endometriosis pain. Researchers want to know if starting it immediately after surgery provides extra benefits. The study will measure overall quality of life at 6 months to see if Rel-CT is superior to surgery alone. We are looking to enroll 110 participants, but the current recruitment status is unclear.

Study design
This is an unblinded randomized controlled trial, meaning you will know if you are taking the medication or not, and you will be randomly assigned to one of two groups. The study plans to enroll 110 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary outcome will be measured at 6 months after surgery.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06439524

The Effect of Medical Management Following Excisional Surgery for Endometriosis: A Randomized Controlled Trial

Recruiting
PHASE3Ages 18+InterventionalTreatment
Main Line Health
~110 participants
Updated 2026-06-12 on ClinicalTrials.gov
What's tested:40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetate

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
This study aims to determine if immediate postoperative medical suppression with Regugolix combination therapy (Rel-CT) following excisional surgery for endometriosis is superior to surgery alone.
Measured over 6 months

Conditions

Endometriosis

Explore related trials

Endometriosis

Where it's being run

1 sites across 1 states
Pennsylvania1

Study leadership

  • Jordan Klebanoff, MD · PRINCIPAL_INVESTIGATOR · Main Line Health

Who to contact

Jordan Klebanoff, MD
[email protected]
610-896-4380
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age ≥ 18 years
Planning to undergo an elective laparoscopic or robotic procedure for known or suspected endometriosis

Exclusion

A known contraindication to REL-CT. Contraindications include:
High risk of arterial, venous thrombotic, or thromboembolic disorder
Pregnancy Known osteoporosis
Current or history of breast cancer or other hormone-sensitive malignancies
Known hepatic impairment or disease
Undiagnosed abnormal uterine bleeding
Known hypersensitivity to components of Rel-CT
The patient did not discontinue hormonal suppression within the required timeline:
Primary language other than English/Spanish
Interested in pregnancy within the 6 months following the surgical procedure.
If pregnancy test performed during pre-surgical work up is positive, the patient will no longer be a candidate for endometriosis surgery and will therefore not be eligible for the study.
Patients without histologic evidence of endometriosis following their surgical procedure will be removed from the study prior to receiving the study intervention.
Patients who undergo a surgical intervention more invasive than the planned laparoscopic or robotic excisional surgery, such as open abdominal surgical repair, will be removed from the study prior to receiving the study intervention.

What this trial measures

  • This study aims to determine if immediate postoperative medical suppression with Regugolix combination therapy (Rel-CT) following excisional surgery for endometriosis is superior to surgery alone.6 months

    The study will assess quality of life via change in total Endometriosis Health Profile 30 (EHP-30) scores following excisional surgery for endometriosis from baseline to 6 months postoperatively.